entertainment -WSS

entertainment

author：hotspot 2025-08-23 08:57:56 - browse：6187

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： For Medicare Advantage, Democrats want stronger protections around AI

hotspot

explore

WSS

A disappointing year of Humira biosimilars

KalVista pill reduced swelling 'attacks' caused by genetic disease

The biotech scorecard for Q3: 15 stock

Use doctors trained outside the U.S. to ease the physician shortage

The wait for US passports is creating travel purgatory and snarling summer plans

STAT wants to know your pick for a great summer read or listen

entertainment

entertainment

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

'Screen and refer' systems are hurting patients

Sports medicine is finally prioritizing gender equality

BioAge raises $170M for combination therapy with Zepbound

BioMarin wins approval for gene therapy to treat hemophilia A

Biogen Alzheimer’s drug launch off to slow start

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Dexcom's push to bring CGM to type 2 diabetes patients

Medical records are filled with copy

Canadians with cystic fibrosis outlive Americans by a decade

knowledge

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Industry veterans launch new biotech VC with $310M

What should King Charles tell the public about his cancer?

A letter from the executive editor: The 2023 STATUS List

Readout LOUD podcast: How biotech is using artificial intelligence

To avoid data mishandling cases, universities eye AI and other tools

explore

hotspot

explore

entertainment